Achilles joins Cen­ter for Break­through Med­i­cines site near Philadel­phia; Catal­ent adds new suites at Kansas City fa­cil­i­ty

A cell ther­a­py bio­phar­ma is join­ing the Cen­ter for Break­through Med­i­cines.

Lon­don-based Achilles Ther­a­peu­tics has inked a deal to get sup­plies for its Phase I/IIa clin­i­cal tri­als in non-small cell lung can­cer and metasta­t­ic or re­cur­rent melanoma pa­tients.

CBM will man­u­fac­ture the T-cell ther­a­py for tri­als.

“We look for­ward to mo­bi­liz­ing our world-class cell ther­a­py ca­pa­bil­i­ties, with our first wave of cell ther­a­py suites to en­able Achilles to ac­cel­er­ate the de­vel­op­ment of their flag­ship pre­ci­sion T-cell prod­uct can­di­date,” head of cell ther­a­py at CBM John Lee said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER